Version 1
: Received: 22 January 2023 / Approved: 24 January 2023 / Online: 24 January 2023 (03:27:37 CET)
Version 2
: Received: 15 February 2023 / Approved: 16 February 2023 / Online: 16 February 2023 (07:54:31 CET)
Version 3
: Received: 3 March 2023 / Approved: 6 March 2023 / Online: 6 March 2023 (01:53:16 CET)
Hendekli, C.M. Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune-Related Adverse Events along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy against Tumor Plasticity. Journal of Cancer Research and Clinical Oncology 2023, doi:10.1007/s00432-023-04718-x.
Hendekli, C.M. Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune-Related Adverse Events along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy against Tumor Plasticity. Journal of Cancer Research and Clinical Oncology 2023, doi:10.1007/s00432-023-04718-x.
Hendekli, C.M. Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune-Related Adverse Events along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy against Tumor Plasticity. Journal of Cancer Research and Clinical Oncology 2023, doi:10.1007/s00432-023-04718-x.
Hendekli, C.M. Drawbacks of Immune Checkpoint Inhibition and Rigorous Management for Immune-Related Adverse Events along with a Mathematical Model to Assess Therapy Success and Optimum Therapy Duration and a Strategy against Tumor Plasticity. Journal of Cancer Research and Clinical Oncology 2023, doi:10.1007/s00432-023-04718-x.
Abstract
Immune checkpoint inhibition therapy (ICIT) is an emerging field in oncology especially opening new horizons to chemotherapy refractory patients. This paper provides deep insight into immune related adverse events (irAEs) posing a major challenge and drawback to ICIT, and presents right management strategies for very complex complications. Moreover, a non-linear mathematical approach to measure the ICIT success rate and a strategy to overcome or to delay the progression after initial good response to ICIT in a subset of patients are presented, respectively.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
16 February 2023
Commenter:
C. Mehmet Hendekli
Commenter's Conflict of Interests:
Author
Comment:
1) Last sentence of abstract is modified. 2) A new subsection is added on pages 23-24. 3) A mathematical model is added in section "DISCUSSION" (changes start in the last paragraph of page 27 and end in the first paragraph of page 29). 4) Three more references are added (62-64). The subsequent ones are simply renumbered.
Commenter: C. Mehmet Hendekli
Commenter's Conflict of Interests: Author
2) A new subsection is added on pages 23-24.
3) A mathematical model is added in section "DISCUSSION" (changes start in the last paragraph of page 27 and end in the first paragraph of page 29).
4) Three more references are added (62-64). The subsequent ones are simply renumbered.